CD44 and hepatocellular carcinoma: Most importantly, we demonstrate that, in CD44 overexpressing HCC cell lines, the CD44–PRG4 interaction leads to an increased sensitivity to the antiproliferative action of the multi-kinase inhibitors sorafenib and regorafenib in vitro.